Actively Recruiting
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
Led by Sichuan University · Updated on 2025-02-28
43
Participants Needed
1
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer
CONDITIONS
Official Title
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years to 75 years
- ECOG performance status score of 0-1
- Histologically confirmed pancreatic ductal adenocarcinoma, stage I-III, with complete tumor removal (R0 resection)
- No prior neoadjuvant therapy before surgery
- Adequate bone marrow and organ function
- Use of effective contraception for patients who can bear children
- Signed informed consent
- Ability to follow study procedures and attend follow-up visits
You will not qualify if you...
- Received chemotherapy, radiation, or immunotherapy within 2 weeks before the first vaccine dose
- History of other cancers except certain treated types like cervical cancer in situ or treated squamous cell carcinoma
- Uncontrolled infections or serious heart conditions such as heart failure, unstable angina, or arrhythmias
- HIV infection or active hepatitis B or C
- Uncontrolled coronary artery disease, asthma, cerebrovascular disease, or other conditions considered unsuitable by investigators
- Autoimmune diseases or immunodeficiencies treated with immunosuppressive drugs
- Pregnant or breastfeeding women
- Vaccination with other vaccines within 4 weeks before or 8 weeks after study vaccination
- Severe allergy to any vaccine in the past
- Allergy to the investigational vaccine or its components
- Substance abuse or inability to comply due to psychological or social reasons
- Significant weight loss (10% or more) within 6 weeks prior to enrollment
- Any other factors that may affect safety or study compliance
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
West China Hospital, Sichuan University
Chengdu, Sichuan, China, 610000
Actively Recruiting
Research Team
Z
zhong Wu, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here